Minerva Announces Leadership Transition [Yahoo! Finance]
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: Yahoo! Finance
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President. Over his 16 years with the Company, he played a central role in establishing Minerva's operational, financial, and clinical development foundation. “We are deeply grateful for Geoff's exceptional leadership, dedication and foundational contributions,” said Dr. Remy Luthringer, Executive Chairm
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Announces Leadership TransitionGlobeNewswire
- Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaGlobeNewswire
- Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia [Seeking Alpha]Seeking Alpha
- Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 [Yahoo! Finance]Yahoo! Finance
- Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026GlobeNewswire
NERV
Earnings
- 5/13/25 - Beat
NERV
Analyst Actions
- 3/12/26 - HC Wainwright
NERV
Sec Filings
- 4/2/26 - Form 8-K
- 4/1/26 - Form 4
- 3/31/26 - Form 144
- NERV's page on the SEC website